CLCF1 and hepatocellular carcinoma: For example, miR-30a-5p can inhibit glycolysis and increase sensitivity to sorafenib through targeting CLCF1 in HCC, indicating modulating the expression level of miR-30a-5p has a promising therapeutic effect on HCC patients (Zhang et al., 2020).